Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE006476 |
YEM_ID: | YEM-509 |
ID: | TCMBANKHE006476/YEM-509 |
植物拉丁名: |
|
功能与主治: | To relieve pain, astringe intestines, suppress cough./Pain in heart and abdomen, chronic diarrhea, chronic dysentery, dry cough without phlegm. |
药用植物名: | 鸦片|罂粟 |
药名: | 罂粟 |
来源: | 云南民族药物志：第三卷 |
药用部位: | latex from unripe capsules |
使用民族: | 傣族/基诺族/佤族/彝族 |
药味: | Mild; Sour |
经络: | Lung; Large Intestine; Kidney |
临床特征: | 1. Slowing the rate of breathing and depressing the cough reflex, and exerting an antitussive effect. 2. Relaxing the smo9th muscles of gastrointestinal tract and trachea. 3. Being an analgesic acting on the central nervous system |
治疗类型: | 收涩 |
TCM_ID_id: | 7006 |
TCMSP_id: | 674 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN001372 | methylconiferin | C17H24O8 | 356.4 g/mol | COCC=CC1=CC(=C(C=C1)OC2C(C(C(C(O2)CO)O)O)O)OC | |
| TCMBANKIN003265 | portulal | C20H32O4 | 336.47 | CC1CC2(CC(=CCCC2C1(CCC(=CCO)CO)CO)C)C=O | |
| TCMBANKIN003632 | 1-o-methyl-3,5-o-dicaffeoyl quinic acid methyl ester | 1-o-methyl-3,5-o-dicaffeoyl quinicacid methylester | C27H28O12 | CCOC(=O)C1(CC(C(C(C1)OC(=O)C=CC2=CC(=C(C=C2)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)O)O | |
| TCMBANKIN005868 | neopine | CCG-39441; Neopin; C09594; KBio3_001981; EINECS 207-387-7; Spectrum2_001745; Spectrum4_001139; Spectrum5_001754; Neopine; DTXSID80196910; BSPBio_002761; SPBio_001850; SCHEMBL679477; UNII-TM43JB0IA8; 467-14-1; KBioGR_001657; (5alpha,6alpha)-8,14-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; 27115-17-9; CHEBI:7509; Spectrum3_001011; TM43JB0IA8; BRD-K34252131-001-02-0; beta-Codeine | C18H21NO3 | 299.4 g/mol | CN1CCC23C4C(CC=C2C1CC5=C3C(=C(C=C5)OC)O4)O |
| TCMBANKIN006628 | codamine | C20H25NO4 | 343.4 g/mol | CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)O)OC | |
| TCMBANKIN008543 | cyclolaudenol | C31H52O | 440.74 | CC(CCC(C)C(=C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)O)C)C | |
| TCMBANKIN009031 | scoulerine | CHEMBL1395394; AKOS032949038; CAS-6451-73-6; AC1LMC5I; Scoulerine; ZINC28465423; (+)-Scoulerine; 4CN-3063; (13aR)-3,10-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,9-diol; BDBM50429050; NCGC00016674-01 | C19H21NO4 | 327.4 g/mol | COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)O)C=C1)O |
| TCMBANKIN009689 | gomaline | C30H42N4O2 | 490.7 g/mol | CN1CCCN(C(=O)CC1C2=CC=CC=C2)CCCCN3CCCN(C(CC3=O)C4=CC=CC=C4)C | |
| TCMBANKIN010463 | cycloartenyl ferulate | C40H58O4 | 602.9 g/mol | CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)OC(=O)C=CC6=CC(=C(C=C6)O)OC)C)C | |
| TCMBANKIN012043 | hydrocotarnine | CAS-5985-00-2; 5985-00-2; Tox21_110552; NSC99784; 1,5-g]isoquinoline, 5,6,7,8-tetrahydro-4-methoxy-6-methyl-, hydrobromide; HYDROCOFARMINE HBR; Tox21_110552_1; FT-0627128; CCG-38859; SR-01000842151-3; HMS1569J12; 5,6,7,8-Tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinoline hydrobromide; DSSTox_RID_80849; CHEMBL1569495; SMR001233253; 1,3-Dioxolo(4,5-g)isoquinoline, 5,6,7,8-tetrahydro-4-methoxy-6-methyl-, hydrobromide (1:1); NCGC00016666-01; EN300-191460; XSR2NNV6TM; 8-Methoxy-5,6-methylenedioxy-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrobromide; SR-01000842151; DTXSID9045392; Hydrocotarnine hydrobromide; Prestwick_267; MLS002153904; NSC-99784; AC1O4WGO; DSSTox_GSID_45392; DSSTox_CID_25392; NCGC00016666-06; SCHEMBL4281040; 4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline hydrobromide; UNII-XSR2NNV6TM | C12H15NO3 | 221.25 g/mol | CN1CCC2=CC3=C(C(=C2C1)OC)OCO3 |
| TCMBANKIN013157 | thebaine | C19H21NO3 | 311.4 g/mol | CN1CCC23C4C(=CC=C2C1CC5=C3C(=C(C=C5)OC)O4)OC | |
| TCMBANKIN013783 | xanthatin | C15H18O3 | 246.3 g/mol | CC1CC2C(CC=C1C=CC(=O)C)C(=C)C(=O)O2 | |
| TCMBANKIN013791 | cosbene | C20H32 | CC1=CCCC(=CC2C(C2(C)C)CCC(=CCC1)C)C | ||
| TCMBANKIN014190 | coreximine | C19H21NO4 | 327.37 | COC1=C(C=C2C3CC4=CC(=C(C=C4CN3CCC2=C1)OC)O)O | |
| TCMBANKIN014279 | Papaverrubine B | papaverrubine b | C21H23NO6 | 385.4 g/mol | COC1C2=C(C=CC3=C2OCO3)C4C(O1)C5=CC(=C(C=C5CCN4)OC)OC |
| TCMBANKIN015613 | rhoeadine | C21H21NO6 | 383.39 | CN1CCC2=CC3=C(C=C2C4C1C5=C(C(O4)OC)C6=C(C=C5)OCO6)OCO3 | |
| TCMBANKIN016040 | Palaudine | 5-[(6,7-dimethoxyisoquinolin-1-yl)methyl]-2-methoxy-phenol; 5-[(6,7-dimethoxyisoquinolin-1-yl)methyl]-2-methoxyphenol; Phenol, 5-((6,7-dimethoxy-1-isoquinolinyl)methyl)-2-methoxy-; 5-[(6,7-dimethoxy-1-isoquinolyl)methyl]-2-methoxy-phenol; 18694-10-5; 3'-Hydroxypapaverine; 5-[(6,7-dimethoxy-1-isoquinolyl)methyl]-2-methoxyphenol; palaudine | C19H19NO4 | 325.36 | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)O |
| TCMBANKIN016305 | coriamyrtin | C15H18O5 | 278.3 g/mol | CC(=C)C1C2CC3(C4(CO4)C5C(C3(C1C(=O)O2)O)O5)C | |
| TCMBANKIN018095 | cycloartenone | Cycloartenone; CYCLOARTENONE; CHEMBL226084; 511-63-7 | C30H48O | 424.7 | CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(=O)C5(C)C)C)C |
| TCMBANKIN018692 | pallidiflorin | C16H12O4 | 268.26 g/mol | COC1=CC=C(C=C1)C2=COC3=CC=CC(=C3C2=O)O | |
| TCMBANKIN018844 | launobine | C18H17NO4 | 311.3 g/mol | COC1=C(C2=C(CC3C4=C2C5=C(C=C4CCN3)OCO5)C=C1)O | |
| TCMBANKIN019205 | Cryptogenin | Cryptogenine; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione; cryptogenin; Cholest-5-ene-16,22-dione, 3beta,26-dihydroxy-, (20S,25R)- (8CI); Cryptogenine [French]; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione [French]; BXC9X8B37J; 3beta,26-Dihydroxycholest-5-ene-16,22-dione; UNII-BXC9X8B37J; NSC 93751; Cholest-5-ene-16,22-dione, 3-beta,26-dihydroxy-, (20S,25R)- (8CI); Cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3-beta,25R)-; (3-beta,25R)-3,26-Dihydroxycholest-5-ene-16,22-dione | C27H42O4 | 430.62 | [H+].CC(CCC(=O)C(C)C1C(=O)CC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)CO |
| TCMBANKIN020321 | neoprotoveratrine | C41H63NO15 | 809.9 g/mol | CCC(C)C(=O)OC1C(C2C(CN3CC(CCC3C2(C)O)C)C4C1(C5C(C(C6C7(C5(C4)OC6(C(CC7)OC(=O)C(C)(C(C)O)O)O)C)OC(=O)C)OC(=O)C)O)O | |
| TCMBANKIN020725 | beta-narcotine | AKOS003673314; IDI1_000323; CHEBI:95149; SCHEMBL14386820; β-narcotine; AC1L2EQH; MolPort-006-822-780; 6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; KBio1_000323; DivK1c_000323; CTK8G2016; NINDS_000323; LS-84359; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,R*))- | C22H23NO7 | 413.4 g/mol | CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3 |
| TCMBANKIN020855 | glaziovine | C18H19NO3 | 297.35 | CN1CCC2=CC(=C(C3=C2C1CC34C=CC(=O)C=C4)O)OC | |
| TCMBANKIN020949 | papaverine | Cepaverin; AOB5339; 58-74-2; MFCD00012745; ZINC00056555; NCI60_003183; Drapavel; DSSTox_RID_77939; NCI-C56359; Myobid; BB_NC-0726; H754; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride; Papaverine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Dynovas; Artegodan; Papavarine chlorhydrate; DTXSID9025825; NCGC00094258-03; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; Alapav; Papacon; AIDS000185; NSC35443 (HCL); SMR000058283; KBioGR_000914; Spasmo-Nit; Papavarine hydrochloride; HMS1569F08; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-isoquinoline; DSSTox_CID_5825; Papaverine hydrochloride (JP17/USP); Pameion; NCGC00094258-06; BSPBio_002153; Chlorhydrate de papaverine [French]; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride (1:1); SBB080541; AIDS-000185; Oprea1_387689; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; I01-13837; Optenyl; CTK8G2272; Papaverine Hcl; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Dispamil; Lopac0_000957; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Isoquinoline,7-dimethoxy-1-veratryl-, hydrochloride; MLS000028497; KBio2_005607; Lapav; Ro-Papav; Papanerin-HCl [German]; Cardiospan; Tox21_110226_1; TNP00305; Pavnell; HMS1920F06; LP00957; Pavagrant; SR-01000003098-2; SDCCGMLS-0003037.P003; AC1L1LRO; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 6,7-Dimethoxy-1-veratrylisoquinoline; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); TR-031684; Pavacot; Papaverine hydrochloride, United States Pharmacopeia (USP) Reference Standard; Paveron; Spectrum4_000467; Spectrum_000071; LS-267; SR-01000003098-11; Forpavin; Durapav; Cardoverina; Prestwick2_000583; Papaverine hydrochloride, powder; CCRIS 3804; 5-21-06-00182 (Beilstein Handbook Reference); Paverolan; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline; FT-0631269; ACon1_002094; NCGC00094258-04; EINECS 200-397-2; Papaverine; AC1Q3DLI; CHEMBL98123; Pavadel; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride; 58-74-2 (Parent); InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; REGID_for_CID_6084; BBC/116; Dipav; NCGC00094258-01; P0016; SPBio_002645; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; NCGC00261642-01; PubChem6305; Cerebid; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Oprea1_810508; Vasal; Papanerin; P 3510; 23473EC6BQ; Pharmakon1600-01500459; C06533; Lopac-P-3510; Vaso-Pav; SCHEMBL121268; DivK1c_000321; Papaverina [Italian]; NSC136630; NSC 136630; KBio2_000471; Spectrum3_000537; MLS002222208; component of Copavin; 58-74-2 (FREE BASE ); Therapav; BG00717685; Prestwick1_000583; Pavacen; Copavin; AK-67336; Dilaves; PAP H; 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene, chloride; UNII-23473EC6BQ; NCGC00015810-01; Papaversan; Tox21_500957; DSSTox_GSID_25825; Papaverine chlorohydrate; Papaverine hydrochloride [USAN:JAN]; EINECS 200-502-1; EU-0100957; Robaxapap; NCGC00094258-02; Papaverine hydrochloride [USP:JAN]; Papaverine, hydrochloride; Papaverine (hydrochloride); PAPAVERINE HYDROCHLORIDE; Prestwick0_000583; MEGxp0_001880; Delapav; D02218; Pavacap; BPBio1_000470; Ceraspan; AS-13262; NCGC00015810-03; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride; Papanerin-hcl; NCGC00015810-12; KB-146860; RS 47; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride; CAS-61-25-6; UOTMYNBWXDUBNX-UHFFFAOYSA-N; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1); Papaverin; ACon1_000238; KBio2_003039; Prestwick3_000583; Pavabid (TN); Papaverine monohydrochloride; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1 &GH; NSC757256; Pavatest; Papaverinium chloride; SR-01000003098; ST077145; ST023301; Pavakey; NSC-35443; BRN 0312930; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); SR-01000003098-9; 61-25-6 (HCL); SPBio_001015; NSC35443; MLS001148655; BSPBio_000426; IDI1_000321; Spectrum2_000978; Pavased; SPECTRUM1500459; Papanerine; NSC-757256; NCGC00094258-05; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)-isoquinoline hydrochloride; KBioSS_000471; HY-18077A; Papaverine hydrochloride, European Pharmacopoeia (EP) Reference Standard; BG01663857; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinolinehydrochloride; S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NINDS_000321; Papalease; Papaverine hydrochlorid; KBio3_001653; Pap-Kaps-150; MolPort-000-847-203; NCGC00015810-02; Isoquinoline, 6,7-dimethoxy-1-veratryl-; API0003748; CCG-40065; CS-5015; BAS 00674058; ARONIS23834; AKOS005111070; 61-25-6; NSC 35443; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; C20H22ClNO4; 1-(3,7-dimethoxyisoquinoline hydrochloride; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride (8CI); Tox21_110226; 6,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Spectrum5_001188; Opera_ID_1617; Prestwick_376; SR-01000003098-4; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; KBio1_000321 | C20H21NO4 | 339.39 | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC |
| TCMBANKIN021575 | glaudine | C22H25NO6 | 399.4 g/mol | CN1CCC2=CC(=C(C=C2C3C1C4=C(C(O3)OC)C5=C(C=C4)OCO5)OC)OC | |
| TCMBANKIN021670 | Thellungianin F | [4-[(Z)-prop-1-enyl]phenyl] 2-methylbutanoate; AC1NT0ZM; thellungianin f | 218.32 | CCC(C)C(=O)OC1=CC=C(C=C1)C=CC | |
| TCMBANKIN021931 | laudanosine | C21H27NO4 | 357.44 | CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC | |
| TCMBANKIN023209 | cotarnine | 4-methoxy-6-methyl-7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium hydroxide; AC1LAXDM; Cotarmine | C12H15NO4 | 237.25 g/mol | CN1CCC2=CC3=C(C(=C2C1O)OC)OCO3 |
| TCMBANKIN025420 | codeine | Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; HSDB 3043; O(3)-methylmorphine; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol; C06174; l-Codeine; CCRIS 7555; Morphine monomethyl ether; C1653_SIGMA; Methylmorphine; Codeine; CHEBI:16714; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol; (5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); Coducept; Norcodeine, N-methyl; 76-57-3; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI); Codicept; Morphine-3-methyl ester; Codeine anhydrous; O3-Methylmorphine; EINECS 200-969-1; Morphine 3-methyl ether; Norcodine, N-methyl; Codein; Morphine-3-methyl ether; STOCK1N-42851; (-)-Codeine; Codeine solution; BB_NC-0138; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI); 7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; C5901_SIGMA; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- | C18H21NO3 | 299.36 | CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O |
| TCMBANKIN025631 | medicagenic acid 3-o-triglucoside | medicagenicacid 3-o-triglucoside | C48H76O21 | 989.1 g/mol | CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C(=O)O)OC6C(C(C(C(O6)CO)O)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)O)O)C)C)C2C1)C)C(=O)O)C |
| TCMBANKIN026380 | pseudomorphine | C34H36N2O6 | 568.7 g/mol | CN1CCC23C4C1CC5=CC(=C(C(=C52)OC3C(C=C4)O)O)C6=C(C7=C8C(=C6)CC9C1C8(CCN9C)C(O7)C(C=C1)O)O | |
| TCMBANKIN026500 | rhoeagenine | C20H19NO6 | 369.4 g/mol | CN1CCC2=CC3=C(C=C2C4C1C5=C(C(O4)O)C6=C(C=C5)OCO6)OCO3 | |
| TCMBANKIN028288 | morphine | (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 | C17H19NO3 | 285.34 | CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O |
| TCMBANKIN031525 | OXYNITIDINE | ZINC01721695; 2,3-dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridin-13(12h)-one; 548-31-2; oxynitidine; ZINC1721695; 6-oxynitidine; DTXSID40203275; CHEMBL488611; NSC 135066; AC1L3YUI; AC1Q6PAY; 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-13-one; NSC135066; NSC-135066; (1,3)Benzodioxolo(5,6-c)phenanthridin-13(12H)-one, 2,3-dimethoxy-12-methyl-; 2,3-Dimethoxy-12-methyl-12H-[1,3]dioxolo-[4',5':4,5]benzo[1,2-c]phenanthridin-13-one; CTK1H1768; 16,17-DIMETHOXY-21-METHYL-5,7-DIOXA-21-AZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(1)?]HENICOSA-1(13),2,4(8),9,11,14,16,18-OCTAEN-20-ONE | C21H17NO5 | 363.36 | CN1C2=C(C=CC3=CC4=C(C=C32)OCO4)C5=CC(=C(C=C5C1=O)OC)OC |
| TCMBANKIN031680 | papyramine | C18H23NO4 | 317.4 g/mol | COC1CC2C3(CCN2C(C4=CC(=C(C=C43)OC)OC)O)C=C1 | |
| TCMBANKIN031702 | M-COUMARIC ACID | 2-propenoic acid, 3-(3-hydroxyphenyl)-, (2E)-; m-coumaricacid; 3-(3-hydroxyphenyl)acrylic acid; CINNAMIC ACID,3-HYDROXY (TRANS); 2-Propenoic acid, 3-(3-hydroxyphenyl)-; 588-30-7; NSC50308; 3-(3-hydroxyphenyl)prop-2-enoic acid; (2E)-3-(3-hydroxyphenyl)acrylic acid; NSC 50308; 3-Coumaric acid; (E)-3-(3-hydroxyphenyl)acrylic acid; Cinnamic acid, m-hydroxy-; (E)-3-(3-Hydroxyphenyl)-2-propenoic acid; C12621; H23007_ALDRICH; InChI=1/C9H8O3/c10-8-3-1-2-7(6-8)4-5-9(11)12/h1-6,10H,(H,11,12)/b5-4; (E)-3-(3-hydroxyphenyl)prop-2-enoic acid; 3-Hydroxycinnamic acid; 2-Propenoic acid, 3-(3-hydroxyphenyl)-, (E)-; trans-3-Hydroxycinnamic acid; EINECS 209-615-0; m-Hydroxycinnamic acid; trans-3-Hydroxycinnamate; NSC 28956; 28180_FLUKA; NSC28956; InChI=1/C9H8O3/c10-8-3-1-2-7(6-8)4-5-9(11)12/h1-6,10H,(H,11,12; m-coumaric acid; AI3-32389; 2-Propenoic acid, 3-(3-hydroxyphenyl)- (9CI) | C9H8O3 | 164.16 | C1=CC(=CC(=C1)O)C=CC(=O)O |
| TCMBANKIN033672 | cyclolaudenone | C31H50O | 438.7 g/mol | CC(CCC(C)C(=C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(=O)C5(C)C)C)C | |
| TCMBANKIN034931 | Narcotoline | 3-(4-hydroxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxy-3H-2-benzofuran-1-one; 6-Methyl-4-hydroxy-5,6,7,8-tetrahydro-5-(3-oxo-4,5-dimethoxy-1,3-dihydroisobenzofuran-1-yl)-1,3-dioxolo[4,5-g]isoquinoline; AC1MRPAC; narcotoline | C21H21NO7 | 399.39 | CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)O)OCO3 |
| TCMBANKIN035916 | meconine | C10H10O4 | 194.18 | COC1=C(C2=C(COC2=O)C=C1)OC | |
| TCMBANKIN039014 | isocrotonylpterosin b | 2-(2,4,6-trimethyl-3-oxo-1,2-dihydroinden-5-yl)ethyl (Z)-but-2-enoate; AC1NSWZ8 | C18H22O3 | 286.4 g/mol | CC=CC(=O)OCCC1=C(C2=C(CC(C2=O)C)C=C1C)C |
| TCMBANKIN039518 | Hispidulin-7-O-glucuronide | ||||
| TCMBANKIN044898 | fluorocarpamine | C20H23N2O3+ | 339.4 g/mol | CC=C1C[NH+]2CCC34C2CC1C(N3C5=CC=CC=C5C4=O)C(=O)OC | |
| TCMBANKIN045638 | beta-Sitosterol-3-O-beta-D-xylopyranoside | AC1O3E0X; beta-sitosterol-3-o-beta-d-xylopyranoside; (2S,3R,4S,5R)-2-[[(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxane-3,4,5-triol; β-sitosterol-3-o-β-d-xylopyranoside; beta-Sitosterol-3-O-beta-D-xylopyranoside_qt | 546.92 | ||
| TCMBANKIN047176 | Sculponeata A | C20H26O5 | C1([H])([H])[C@]([H])(OC(=O)[C@@]2(C([H])([H])[C@]([H])(C(=C([H])[H])[C@@]2([H])O[H])C([H])([H])C3([H])[H])[C@@]34[H])[C@]45[C@]([H])([C@@](OC5([H])[H])([H])OC6([H])[H])[C@@]6(C([H])([H])[H])C1([H])[H ] | ||
| TCMBANKIN048336 | 6-methylcryptoacetalide | C19H24O3 | 300.4 g/mol | CC1CC2(C3=C(C4=C(C(=C3)C)C(CCC4)(C)C)C(=O)O2)OC1 | |
| TCMBANKIN049686 | cycloartenol | CF58DF82-6B90-40E1-B241-3FA99C98DA64; Cycloartenol; 9,19-Cyclolanost-24-en-3-ol, (3beta)-; C01902; 9beta,19-Cyclo-24-lanosten-3beta-ol; SCHEMBL561141; Cycloarterenol; 469-38-5; NSC 670193 | C30H50O | 426.7 g/mol | CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)O)C)C |
| TCMBANKIN057913 | hydrocyanicacid | hydrocyanic acid | HCN | 27.025 g/mol | C#N |
| TCMBANKIN058003 | sanguinarine | Sanguinarine, 8CI); NSC-59270; sanguinarine ; NSC-35607; [1,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-, nitrate,sanguiritrin | C20H14NO4+ | 332.3 g/mol | C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 |
| TCMBANKIN059242 | cyclolinopeptide F | (3S,6S,9S,12S,15S,18S,21S,24S)-18,21-dibenzyl-15-(1H-indol-3-ylmethyl)-6-(2-methylpropyl)-3,9-bis(2-methylsulfinylethyl)-12-propan-2-yl-1,4,7,10,13,16,19,22-octazabicyclo[22.3.0]heptacosane-2,5,8,11,14,17,20,23-octone; CHEMBL3787695; AC1O4QKI; (3S,6S,9S,12S,15S,18S,21S,26aS)-3,6-dibenzyl-9-(1H-indol-3-ylmethyl)-15,21-bis(2-methanesulfinylethyl)-18-(2-methylpropyl)-12-(propan-2-yl)-hexacosahydropyrrolo[1,2-a]1,4,7,10,13,16,19,22-octaazacyclotetracosan-1,4,7,10,13,16,19,22-octone; (3S,6S,9S,12S,15S,18S,21S,26AS)-3,6-DIBENZYL-9-(1H-INDOL-3-YLMETHYL)-12-ISOPROPYL-15,21-BIS(2-METHANESULFINYLETHYL)-18-(2-METHYLPROPYL)-OCTADECAHYDROPYRROLO[1,2-A]1,4,7,10,13,16,19,22-OCTAAZACYCLOTETRACOSAN-1,4,7,10,13,16,19,22-OCTONE; Cyclolinopeptide F; cyclolinopeptide f; cyclolinopeptides f | C55H73N9O10S2 | 1084.4 g/mol | CC(C)CC1C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCS(=O)C)C(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCS(=O)C |
| TCMBANKIN059820 | atractylenolide iii; codonolactone | C15H20O3 | 248.32 | CC1=C2CC3C(=C)CCCC3(CC2(OC1=O)O)C | |
| TCMBANKIN060947 | Sanleng acid | C18H34O5 | 330.46 | CCCCCCCCC(C(C=CC(CCCCC(=O)O)O)O)O | |
| TCMBANKIN061110 | 10-nonacosanol | C29H60O | 424.8 g/mol | CCCCCCCCCCCCCCCCCCCC(CCCCCCCCC)O | |
| TCMBANKIN061320 | cryptopine | C21H23NO5 | 369.41 | CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC | |
| TCMBANKIN061324 | d-reticuline | (S)-(+)-reticuline; (1S)-1-[(3-hydroxy-4-methoxy-phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; CHEBI:16718; 485-19-8; (1S)-1-(3-hydroxy-4-methoxy-benzyl)-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (+)-Reticuline; (1S)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; (1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; C02105;CHEBI:17428; AC1L99KR; (R)-(-)-reticuline; (1R)-1,2,3,4-Tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-7-isoquinolinol; AK552295; (1R)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; C05178; FT-0699770; MFCD28556897; ZINC901258; DTXSID80331501; L-Reticuline; CHEMBL401501; AKOS030242061; (1R)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (R)-Reticuline; (-)-reticuline; SCHEMBL9587509; NCGC00247617-01; 3968-19-2; (R)-Reticuline (>80% ee); CTK1C2641; (S)-Reticuline;reticuline;reticulin | C19H23NO4 | 329.4 g/mol | CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)O)O)OC |
| TCMBANKIN061328 | alkaloid a4 | n-methyl-14-o-desmethyl-epiporphyroxine | C20H21NO6 | 371.38 | CN1CCC2=CC(=C(C=C2C3C1C4=C(C(O3)O)C5=C(C=C4)OCO5)O)OC |
| TCMBANKIN061329 | corytuberine | SCHEMBL11250377; AKOS016023668; CORYTUBERINE, PENTAHYDRATE; NSC406033; NSC-406033; 1,11-Dihydroxy-2,10-dimethoxyaporphine; AC1L874Y; AC1Q7AYD; (+)-corytuberine | C19H21NO4 | 327.4 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)OC)O)O)OC |
| TCMBANKIN061352 | longatin | (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; NSC121869; SMR000059119; (S,R)-Noscapine; C09592; STK054401; BSPBio_000346; 128-62-1; AIDS011873; (3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one; Lopac0_000840; Tocris-1697; Noscapine (TN); alpha-Narcotine; .beta.-Narcotine; alpha-narcotine; EINECS 204-899-2; Noscapine [BAN:INN:JAN]; Coscopin (VAN); L-alpha-Narcotine; 4-27-00-06838 (Beilstein Handbook Reference); 1368-39-4; Lopac-N-9007; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl),(S-(R*,S*))-; L-alpha-Noscapine; CAS-128-62-1; BRN 0099933; BSPBio_002113; SDCCGMLS-0066644.P001; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-,(S-(R*,S*))-; HSDB 3372; KBio2_004117; TNP00110; SPBio_001053; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; NCGC00017174-02; 567-86-2; KBio2_006685; Spectrum5_001276; (-)-alpha-Norcotine; NCGC00017174-01; KBioGR_000872; Spectrum2_000987; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; Noscapinum [INN-Latin]; NCGC00015757-01; Spectrum_001069; KBio3_001613; ST055757; (-)-Narcotine; Spectrum3_000527; 8-Methoxyhydrastin; 5-(6,7-Dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline; L-alpha-2-Methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline; TNP00034; KBio2_001549; Spectrum4_000456; Longactin; 8057-19-0; Noscapina [INN-Spanish]; KBioSS_001549; (-)-3-(2-Methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid; NCGC00016388-01; Narcotine (8CI); 8055-18-3; NCGC00023230-02; AIDS-011873; D01036; CBMicro_048259; SPBio_002565; BIM-0048054.P001; NCI60_004322; Prestwick1_000563; Prestwick3_000563; (-)-.alpha.-Narcotine; Prestwick_959; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; MLS000069475; 363960_ALDRICH; BPBio1_000382; Coscopin; Methoxyhydrastine; Prestwick0_000563; Prestwick2_000563; Noscapine (JP15/USP/INN); AC1NSW29; 5-[(1S)-4,5-dimethoxy-3-methylidene-1H-2-benzofuran-1-yl]-4-methoxy-6,9-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline; narcotine; Noscapine; gnoscopine; Noskapin; α-narcotine | C22H23NO7 | 413.42 g/mol | CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3 |
| TCMBANKIN061465 | papaveraldine | xanthaline | C20H19NO5 | 353.37 g/mol | COC1=C(C=C(C=C1)C(=O)C2=NC=CC3=CC(=C(C=C32)OC)OC)OC |
| TCMBANKIN061665 | hispidulin | 447H887; 5,7,4'-trihydroxy-6-methoxyflavone; Dinatin; 6-methoxyapigenin; LS-173226; CTK8G0189; NSC 122415; BDBM50049395; UNII-N7F61604C2; B6959; 4H-1-Benzopyran-4-one,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-; hispidulin ; ACon1_000933; MLS000728540; NP-001963; ZINC5732241; 4',7-Trihydroxy-6-methoxyflavone; MCULE-3882973229; SCHEMBL514926; HMS3344G13; C10058; 4?,5,7-Trihydroxy-6-methoxyflavone; PubChem SID: 26725244; W1618; MolPort-001-740-838; NSC122415; KS-00001FKN; MEGxp0_000683; Hispidulin; Oprea1_873387; cid_5281628; methoxyapigenin; BRD-K72066874-001-01-0; Flavone,5,7-trihydroxy-6-methoxy-; TCMDC-123942; N7F61604C2; FT-0697687; 1447-88-7; Scutellarein 6-methyl ether; CCRIS 8484; HMS2223A03; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one; 6-methylscutellarein; HY-N1950; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one #; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-chromen-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxychromen-4-one; Flavone, 4',5,7-trihydroxy-6-methoxy-; SMR000445653; AN-49210; 4H-1-Benzopyran-4-one, 5, 7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-; 5,7-Dihydroxy-2-(4-hydroxy-phenyl)-6-methoxy-chromen-4-one; hispidulin(dinatin); AKOS004110694; NCGC00167728-02; 6-methoxy apigenin; 5,7,4''-Trihydroxy-6-methoxyflavone; HUL; 4CN-1206; DTXSID30162786; NCI60_000530; CS-6502; IHFBPDAQLQOCBX-UHFFFAOYSA-N; ST024778; 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-6-METHOXY-; CHEBI:75902; AC1NQYRM; BG01592767; C-56393; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one; NCGC00167728-01; CHEMBL293776; NSC-122415; NCGC00169216-01; Q-100165; 6-O-Methylapigenin; 4H-1-Benzopyran-4-one,5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-; LMPK12111159; 4',5,7-Trihydroxy-6-methoxyflavone; Dinatin; NCI60_000530; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one; AIDS126680; NSC122415; MEGxp0_000683; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-4-chromenone; Hispidulin; ST024778; Oprea1_873387; 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-6-METHOXY-; NSC 122415; ZINC00113457; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-chromen-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxychromen-4-one; Flavone, 4',5,7-trihydroxy-6-methoxy-; SMR000445653; AIDS-126680; ACon1_000933; 4H-1-Benzopyran-4-one, 5, 7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-; MLS000728540; 6-O-Methylapigenin; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-chromone; 1447-88-7; C10058; Scutellarein 6-methyl ether; 4',5,7-Trihydroxy-6-methoxyflavone; 6-methoxyapigenin | C16H12O6 | 300.26 g/mol | COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC=C(C=C3)O)O |
| TCMBANKIN061669 | (-)-discretamine | Prestwick3_000601; (13aS)-3,10-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,9-diol; (13aS)-3,10-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline-2,9-diol; BPBio1_000554; CHEBI:17129; C02106; (13aS)-5,8,13,13a-tetrahydro-3,10-dimethoxy-6H-dibenzo[a,g]quinolizine-2,9-diol; BSPBio_000502; CHEMBL1395394; AKOS032949038; CAS-6451-73-6; AC1LMC5I; Scoulerine; ZINC28465423; (+)-Scoulerine; 4CN-3063; (13aR)-3,10-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,9-diol; BDBM50429050; NCGC00016674-01; scoulerine; (S)-Scoulerine | C19H21NO4 | 327.4 g/mol | COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)O)C=C1)O |
| TCMBANKIN061670 | Isocorypalmine | (13aS)-5,8,13,13a-tetrahydro-3,9,10-trimethoxy-6H-Dibenzo[a,g]quinolizin-2-ol; 483-34-1; 5,8,13,13a-Tetrahydrocolumbamine; AJ-84169; 20504-94-3; SCHEMBL16035972; (-)-Isocorypalmine; BDBM50429057; UNII-YHT108XMMM component KDFKJOFJHSVROC-INIZCTEOSA-N; 6H-Dibenzo(a,g)quinolizin-2-ol, 5,8,13,13a-tetrahydro-3,9,10-trimethoxy-, (S)- (9CI); ZINC30725153; Corydalis L; l-Tetrahydrocolumbamine; l-Isocorypalmine; (S)-3,9,10-Trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinolin-2-ol; 6611AB; AX8235065; ISOCORYPALMINE, (-)-; FT-0670441; AKOS016007096; O10-Methylstepholidine; Tetrahydro-columbamine; C04118; CHEMBL2334891; 5, 8, 13, 13a-tetrahydrocolumbamine; CHEBI:17772; CTK8C0461; HY-N0927; (13aS)-3,9,10-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolin-2-ol; Tetrahydrocolumbamine; (S)-THC; ANW-64713; ST24036047; 13a-alpha-Berbin-2-ol, 3,9,10-trimethoxy- (8CI); 2-O-Desmethyl-L-THP; 1356-03-2; UNII-MX470OL19D; isocorypalmine; AK103526; S-TETRAHYDROCOLUMBAMINE; ACM483341; MX470OL19D; 483-33-0; MolPort-023-332-930; (13aS)-3,9,10-trimethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinolin-2-ol; TC-153458; (13aS)-5, 8,13,13a-tetrahydro-3, 9,10-trimethoxy-6H-dibenzo [a, g] quinolizin-2-ol; (S)-Tetrahydrocolumbamine; AC1L98XN; KB-211380; Columbamine, tetrahydro- (7CI); tetrahydrocolumbamine | C20H23NO4 | 341.4 g/mol | COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)O)C=C1)OC |
| TCMBANKIN061913 | porphyroxine | papaverrubine d; papaverrubine c | C20H21NO6 | 371.4 g/mol | COC1C2=C(C=CC3=C2OCO3)C4C(O1)C5=CC(=C(C=C5CCN4)OC)O |
| TCMBANKIN061914 | papaverrubine e | papaverrubine a | C20H19NO6 | 369.4 g/mol | COC1C2=C(C=CC3=C2OCO3)C4C(O1)C5=CC6=C(C=C5CCN4)OCO6 |
| TCMBANKIN005868 | neopine | CCG-39441; Neopin; C09594; KBio3_001981; EINECS 207-387-7; Spectrum2_001745; Spectrum4_001139; Spectrum5_001754; Neopine; DTXSID80196910; BSPBio_002761; SPBio_001850; SCHEMBL679477; UNII-TM43JB0IA8; 467-14-1; KBioGR_001657; (5alpha,6alpha)-8,14-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; 27115-17-9; CHEBI:7509; Spectrum3_001011; TM43JB0IA8; BRD-K34252131-001-02-0; beta-Codeine | C18H21NO3 | 299.4 g/mol | CN1CCC23C4C(CC=C2C1CC5=C3C(=C(C=C5)OC)O4)O |
| TCMBANKIN013157 | thebaine | C19H21NO3 | 311.4 g/mol | CN1CCC23C4C(=CC=C2C1CC5=C3C(=C(C=C5)OC)O4)OC | |
| TCMBANKIN014161 | Protoporphyrin | 553-12-8 (FREE ACID); NSC2632 (FREE ACID); protoporphyrin; Ferrocytochrome; PROTOPORPHYRIN (PP); Ferrocytochrome b-561 | C34H34N4O4 | 562.66 | CC1=C(C2=NC1=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=C2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)C=C)C.[Fe+2] |
| TCMBANKIN014279 | Papaverrubine B | papaverrubine b | C21H23NO6 | 385.4 g/mol | COC1C2=C(C=CC3=C2OCO3)C4C(O1)C5=CC(=C(C=C5CCN4)OC)OC |
| TCMBANKIN018095 | cycloartenone | Cycloartenone; CYCLOARTENONE; CHEMBL226084; 511-63-7 | C30H48O | 424.7 | CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(=O)C5(C)C)C)C |
| TCMBANKIN018844 | launobine | C18H17NO4 | 311.3 g/mol | COC1=C(C2=C(CC3C4=C2C5=C(C=C4CCN3)OCO5)C=C1)O | |
| TCMBANKIN019205 | Cryptogenin | Cryptogenine; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione; cryptogenin; Cholest-5-ene-16,22-dione, 3beta,26-dihydroxy-, (20S,25R)- (8CI); Cryptogenine [French]; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione [French]; BXC9X8B37J; 3beta,26-Dihydroxycholest-5-ene-16,22-dione; UNII-BXC9X8B37J; NSC 93751; Cholest-5-ene-16,22-dione, 3-beta,26-dihydroxy-, (20S,25R)- (8CI); Cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3-beta,25R)-; (3-beta,25R)-3,26-Dihydroxycholest-5-ene-16,22-dione | C27H42O4 | 430.62 | [H+].CC(CCC(=O)C(C)C1C(=O)CC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)CO |
| TCMBANKIN020321 | neoprotoveratrine | C41H63NO15 | 809.9 g/mol | CCC(C)C(=O)OC1C(C2C(CN3CC(CCC3C2(C)O)C)C4C1(C5C(C(C6C7(C5(C4)OC6(C(CC7)OC(=O)C(C)(C(C)O)O)O)C)OC(=O)C)OC(=O)C)O)O | |
| TCMBANKIN020725 | beta-narcotine | AKOS003673314; IDI1_000323; CHEBI:95149; SCHEMBL14386820; β-narcotine; AC1L2EQH; MolPort-006-822-780; 6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; KBio1_000323; DivK1c_000323; CTK8G2016; NINDS_000323; LS-84359; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,R*))- | C22H23NO7 | 413.4 g/mol | CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3 |
| TCMBANKIN020949 | papaverine | Cepaverin; AOB5339; 58-74-2; MFCD00012745; ZINC00056555; NCI60_003183; Drapavel; DSSTox_RID_77939; NCI-C56359; Myobid; BB_NC-0726; H754; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride; Papaverine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Dynovas; Artegodan; Papavarine chlorhydrate; DTXSID9025825; NCGC00094258-03; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; Alapav; Papacon; AIDS000185; NSC35443 (HCL); SMR000058283; KBioGR_000914; Spasmo-Nit; Papavarine hydrochloride; HMS1569F08; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-isoquinoline; DSSTox_CID_5825; Papaverine hydrochloride (JP17/USP); Pameion; NCGC00094258-06; BSPBio_002153; Chlorhydrate de papaverine [French]; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride (1:1); SBB080541; AIDS-000185; Oprea1_387689; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; I01-13837; Optenyl; CTK8G2272; Papaverine Hcl; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Dispamil; Lopac0_000957; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Isoquinoline,7-dimethoxy-1-veratryl-, hydrochloride; MLS000028497; KBio2_005607; Lapav; Ro-Papav; Papanerin-HCl [German]; Cardiospan; Tox21_110226_1; TNP00305; Pavnell; HMS1920F06; LP00957; Pavagrant; SR-01000003098-2; SDCCGMLS-0003037.P003; AC1L1LRO; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 6,7-Dimethoxy-1-veratrylisoquinoline; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); TR-031684; Pavacot; Papaverine hydrochloride, United States Pharmacopeia (USP) Reference Standard; Paveron; Spectrum4_000467; Spectrum_000071; LS-267; SR-01000003098-11; Forpavin; Durapav; Cardoverina; Prestwick2_000583; Papaverine hydrochloride, powder; CCRIS 3804; 5-21-06-00182 (Beilstein Handbook Reference); Paverolan; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline; FT-0631269; ACon1_002094; NCGC00094258-04; EINECS 200-397-2; Papaverine; AC1Q3DLI; CHEMBL98123; Pavadel; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride; 58-74-2 (Parent); InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; REGID_for_CID_6084; BBC/116; Dipav; NCGC00094258-01; P0016; SPBio_002645; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; NCGC00261642-01; PubChem6305; Cerebid; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Oprea1_810508; Vasal; Papanerin; P 3510; 23473EC6BQ; Pharmakon1600-01500459; C06533; Lopac-P-3510; Vaso-Pav; SCHEMBL121268; DivK1c_000321; Papaverina [Italian]; NSC136630; NSC 136630; KBio2_000471; Spectrum3_000537; MLS002222208; component of Copavin; 58-74-2 (FREE BASE ); Therapav; BG00717685; Prestwick1_000583; Pavacen; Copavin; AK-67336; Dilaves; PAP H; 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene, chloride; UNII-23473EC6BQ; NCGC00015810-01; Papaversan; Tox21_500957; DSSTox_GSID_25825; Papaverine chlorohydrate; Papaverine hydrochloride [USAN:JAN]; EINECS 200-502-1; EU-0100957; Robaxapap; NCGC00094258-02; Papaverine hydrochloride [USP:JAN]; Papaverine, hydrochloride; Papaverine (hydrochloride); PAPAVERINE HYDROCHLORIDE; Prestwick0_000583; MEGxp0_001880; Delapav; D02218; Pavacap; BPBio1_000470; Ceraspan; AS-13262; NCGC00015810-03; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride; Papanerin-hcl; NCGC00015810-12; KB-146860; RS 47; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride; CAS-61-25-6; UOTMYNBWXDUBNX-UHFFFAOYSA-N; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1); Papaverin; ACon1_000238; KBio2_003039; Prestwick3_000583; Pavabid (TN); Papaverine monohydrochloride; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1 &GH; NSC757256; Pavatest; Papaverinium chloride; SR-01000003098; ST077145; ST023301; Pavakey; NSC-35443; BRN 0312930; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); SR-01000003098-9; 61-25-6 (HCL); SPBio_001015; NSC35443; MLS001148655; BSPBio_000426; IDI1_000321; Spectrum2_000978; Pavased; SPECTRUM1500459; Papanerine; NSC-757256; NCGC00094258-05; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)-isoquinoline hydrochloride; KBioSS_000471; HY-18077A; Papaverine hydrochloride, European Pharmacopoeia (EP) Reference Standard; BG01663857; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinolinehydrochloride; S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NINDS_000321; Papalease; Papaverine hydrochlorid; KBio3_001653; Pap-Kaps-150; MolPort-000-847-203; NCGC00015810-02; Isoquinoline, 6,7-dimethoxy-1-veratryl-; API0003748; CCG-40065; CS-5015; BAS 00674058; ARONIS23834; AKOS005111070; 61-25-6; NSC 35443; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; C20H22ClNO4; 1-(3,7-dimethoxyisoquinoline hydrochloride; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride (8CI); Tox21_110226; 6,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Spectrum5_001188; Opera_ID_1617; Prestwick_376; SR-01000003098-4; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; KBio1_000321 | C20H21NO4 | 339.39 | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC |
| TCMBANKIN021575 | glaudine | C22H25NO6 | 399.4 g/mol | CN1CCC2=CC(=C(C=C2C3C1C4=C(C(O3)OC)C5=C(C=C4)OCO5)OC)OC | |
| TCMBANKIN021670 | Thellungianin F | [4-[(Z)-prop-1-enyl]phenyl] 2-methylbutanoate; AC1NT0ZM; thellungianin f | 218.32 | CCC(C)C(=O)OC1=CC=C(C=C1)C=CC | |
| TCMBANKIN021931 | laudanosine | C21H27NO4 | 357.44 | CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC | |
| TCMBANKIN025334 | parasorbic acid | Parascorbic acid; Kyselina paraskorbova; CHEBI:7926; AC1L9BCD; (+)-(6S)-PARASORBIC ACID; (2S)-2-methyl-2,3-dihydropyran-6-one; gamma-Hexenolactone; parasorbicacid; DCN48OUK3T; AKOS006278774; (S)-(+)-5,6-Dihydro-6-methyl-2H-pyran-2-one; Sorbic oil; C08502; Kyselina paraskorbova [Czech]; CHEMBL2252704; 2-Hexenoic acid, 5-hydroxy-, delta-lactone; Parasorbic acid; UNII-DCN48OUK3T; 2-Hexen-5,1-olide; 10048-32-5; (+)-Parasorbinsaeure [German]; (s)-2-hexen-5-olide; 2H-Pyran-2-one, 5,6-dihydro-6-methyl-, (6S)-; 5-17-09-00130 (Beilstein Handbook Reference); (+)-Parasorbinsaeure; BRN 0080685; SCHEMBL2686203; Hexenollactone | C6H8O2 | 112.13 g/mol | CC1CC=CC(=O)O1 |
| TCMBANKIN025420 | codeine | Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; HSDB 3043; O(3)-methylmorphine; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol; C06174; l-Codeine; CCRIS 7555; Morphine monomethyl ether; C1653_SIGMA; Methylmorphine; Codeine; CHEBI:16714; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol; (5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); Coducept; Norcodeine, N-methyl; 76-57-3; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI); Codicept; Morphine-3-methyl ester; Codeine anhydrous; O3-Methylmorphine; EINECS 200-969-1; Morphine 3-methyl ether; Norcodine, N-methyl; Codein; Morphine-3-methyl ether; STOCK1N-42851; (-)-Codeine; Codeine solution; BB_NC-0138; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI); 7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; C5901_SIGMA; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- | C18H21NO3 | 299.36 | CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O |
| TCMBANKIN028288 | morphine | (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 | C17H19NO3 | 285.34 | CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O |
| TCMBANKIN028295 | retrorsine | .beta.-Longilobine; BCJMNZRQJAVDLD-XRVQXMHSSA-N; RETRORSINE | C18H25NO6 | 351.4 g/mol | CC=C1CC(C(C(=O)OCC2=CCN3C2C(CC3)OC1=O)(CO)O)C |
| TCMBANKIN034931 | Narcotoline | 3-(4-hydroxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxy-3H-2-benzofuran-1-one; 6-Methyl-4-hydroxy-5,6,7,8-tetrahydro-5-(3-oxo-4,5-dimethoxy-1,3-dihydroisobenzofuran-1-yl)-1,3-dioxolo[4,5-g]isoquinoline; AC1MRPAC; narcotoline | C21H21NO7 | 399.39 | CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)O)OCO3 |
| TCMBANKIN036915 | morroniside | Morroniside; HMS2205G07; SMR001397097; MLS002472991; CHEMBL2136065 | C17H26O11 | 406 | [C@@]1([H])(O[H])C([H])([H])[C@@]([H])(C(C(OC([H])([H])[H])=O)=C([H])O[C@@]2([H])O[C@@]3([H])O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]3([H])O[H])[C@@]2([H])[C@]([H])(C([H])([H])[ H])O1 |
| TCMBANKIN044898 | fluorocarpamine | C20H23N2O3+ | 339.4 g/mol | CC=C1C[NH+]2CCC34C2CC1C(N3C5=CC=CC=C5C4=O)C(=O)OC | |
| TCMBANKIN049686 | cycloartenol | CF58DF82-6B90-40E1-B241-3FA99C98DA64; Cycloartenol; 9,19-Cyclolanost-24-en-3-ol, (3beta)-; C01902; 9beta,19-Cyclo-24-lanosten-3beta-ol; SCHEMBL561141; Cycloarterenol; 469-38-5; NSC 670193 | C30H50O | 426.7 g/mol | CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)O)C)C |
| TCMBANKIN058003 | sanguinarine | Sanguinarine, 8CI); NSC-59270; sanguinarine ; NSC-35607; [1,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-, nitrate,sanguiritrin | C20H14NO4+ | 332.3 g/mol | C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 |
| TCMBANKIN058114 | trans-caffeic acid | 3-(3,4-dihydroxy-phenyl)-acrylic acid; caffeic acid; Caffeate; Lopac-C-0625; 71693-97-5; DivK1c_006624; KBio2_007302; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NCGC00015206-02; CAS-3331-39-5; 60020_FLUKA; AI3-63211; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC623438; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; KBio2_004734; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; CHEMBL1320034; AIDS-002287; AIDS002287; 501-16-6; CHEBI:36281; Prestwick1_000902; KBio1_001568; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; AKOS000273846; OR1165; SMR000058214; Spectrum2_001612; 3,4-dihydroxycinnamate; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; KOP; AC1NO658; CCRIS 847; Caffeic acid dehydrogenation homopolymer; SPECTRUM1503987; Spectrum4_001694; SCHEMBL3682144; NCGC00017364-01; NCGC00022654-08; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; 78734C5A-1281-44D4-B8A0-A3188AD437E3; cis-Caffeic acid; 3-(3,4-dihydroxyphenyl)acrylic acid; Cinnamic acid, 3,4-dihydroxy-; KBioGR_001988; 3,4-Dihydroxybenzeneacrylic acid; 3,4-dihydroxycinnamic acid; trans-caffeic acid; AIDS-026339; NCGC00015206-01; HSDB 7088; ZINC4482687; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-dihydroxyphenyl)prop-2-enoate; Isocaffeic acid; SBB006475; InChI=1/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2; NCGC00017364-02; EU-0100208; C01197; MolPort-001-759-162; KBioSS_002166; Caffeic acid pure; caffeic acid ; trans-Caffeate; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; NSC 57197; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; Spectrum_001686; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; KBio2_002166; Caffeic acid, cis-; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3,4-Dihydroxybenzeneacrylate; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; 4361-87-9; 3,4-Dihydroxy-trans-cinnamate; caffeicacid; AR-360/40806927; EINECS 206-361-2; 60018_FLUKA; Caffeic acid polymer; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; NCGC00022654-04; ZX-AL002121; C0625_SIGMA; SDCCGMLS-0002982.P003; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; SPBio_001643; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); NCGC00017364-03; 3-(3,4-dihydroxyphenyl)prop-2-enoic acid; AC1LU7RL; SPBio_002943; CHEBI:16433; AIDS026339; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; CHEBI:17395; TNP00311; SpecPlus_000528; Prestwick0_000902; MLS000069738; 3,4-dihydroxy-cinnamic acid; 3-(3,4-Dihydroxyphenyl)propenoic acid; NCI60_004400; NSC57197; Caffeic; Lopac-C-0625; NCGC00015206-01; Caffeic acid; cis-Caffeic acid; NCGC00017364-01; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; C01481; 331-39-5; NCGC00015206-02; CAS-3331-39-5; 3,4-Dihydroxycinnamic acid; CHEBI:17395; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; TNP00311; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeate; 1- coffee acid | C9H8O4 | 180.16 g/mol | C1=CC(=C(C=C1C=CC(=O)O)O)O |
| TCMBANKIN059820 | atractylenolide iii; codonolactone | C15H20O3 | 248.32 | CC1=C2CC3C(=C)CCCC3(CC2(OC1=O)O)C | |
| TCMBANKIN060679 | stigmasterol | C29H48O | 412.7 g/mol | CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C | |
| TCMBANKIN060680 | stigmasterol-3-glucoside | C35H58O6 | 574.83 g/mol | CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C | |
| TCMBANKIN060947 | Sanleng acid | C18H34O5 | 330.46 | CCCCCCCCC(C(C=CC(CCCCC(=O)O)O)O)O | |
| TCMBANKIN061104 | 11-oxotriacontanoic acid | C30H58O3 | 466.8 g/mol | CCCCCCCCCCCCCCCCCCCC(=O)CCCCCCCCCC(=O)O | |
| TCMBANKIN061320 | cryptopine | C21H23NO5 | 369.41 | CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC | |
| TCMBANKIN061324 | d-reticuline | (S)-(+)-reticuline; (1S)-1-[(3-hydroxy-4-methoxy-phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; CHEBI:16718; 485-19-8; (1S)-1-(3-hydroxy-4-methoxy-benzyl)-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (+)-Reticuline; (1S)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; (1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; C02105;CHEBI:17428; AC1L99KR; (R)-(-)-reticuline; (1R)-1,2,3,4-Tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-7-isoquinolinol; AK552295; (1R)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; C05178; FT-0699770; MFCD28556897; ZINC901258; DTXSID80331501; L-Reticuline; CHEMBL401501; AKOS030242061; (1R)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (R)-Reticuline; (-)-reticuline; SCHEMBL9587509; NCGC00247617-01; 3968-19-2; (R)-Reticuline (>80% ee); CTK1C2641; (S)-Reticuline;reticuline;reticulin | C19H23NO4 | 329.4 g/mol | CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)O)O)OC |
| TCMBANKIN061334 | glaucine | AC1LL50T; (R)-5,6,6a,7-Tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo(de,g)quinoline; 38325-02-9; ZINC792622; EINECS 253-881-0; 4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (R)-; FT-0698454; (?)-Glaucine; RUZIUYOSRDWYQF-OAHLLOKOSA-N; l-Glaucine; DTXSID70191691; (R)-5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo[de,g]quinoline; Glauvent ;(-)-glaucine; Bromcholitin; (+)-Glaucine; AIDS011385; GLAUCINE,(D); Glaucine; 6a.alpha.-Aporphine, 1,2,9,10-tetramethoxy-; NSC34396; S-(+)-Glaucine; C09446; Glaucine fumarate; BB_NC-0833; d-Glaucine; 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (S)-; Boldine dimethyl ether; 475-81-0; AIDS-011385 | C21H25NO4 | 355.43 | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC)OC)OC |
| TCMBANKIN061352 | longatin | (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; NSC121869; SMR000059119; (S,R)-Noscapine; C09592; STK054401; BSPBio_000346; 128-62-1; AIDS011873; (3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one; Lopac0_000840; Tocris-1697; Noscapine (TN); alpha-Narcotine; .beta.-Narcotine; alpha-narcotine; EINECS 204-899-2; Noscapine [BAN:INN:JAN]; Coscopin (VAN); L-alpha-Narcotine; 4-27-00-06838 (Beilstein Handbook Reference); 1368-39-4; Lopac-N-9007; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl),(S-(R*,S*))-; L-alpha-Noscapine; CAS-128-62-1; BRN 0099933; BSPBio_002113; SDCCGMLS-0066644.P001; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-,(S-(R*,S*))-; HSDB 3372; KBio2_004117; TNP00110; SPBio_001053; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; NCGC00017174-02; 567-86-2; KBio2_006685; Spectrum5_001276; (-)-alpha-Norcotine; NCGC00017174-01; KBioGR_000872; Spectrum2_000987; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; Noscapinum [INN-Latin]; NCGC00015757-01; Spectrum_001069; KBio3_001613; ST055757; (-)-Narcotine; Spectrum3_000527; 8-Methoxyhydrastin; 5-(6,7-Dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline; L-alpha-2-Methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline; TNP00034; KBio2_001549; Spectrum4_000456; Longactin; 8057-19-0; Noscapina [INN-Spanish]; KBioSS_001549; (-)-3-(2-Methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid; NCGC00016388-01; Narcotine (8CI); 8055-18-3; NCGC00023230-02; AIDS-011873; D01036; CBMicro_048259; SPBio_002565; BIM-0048054.P001; NCI60_004322; Prestwick1_000563; Prestwick3_000563; (-)-.alpha.-Narcotine; Prestwick_959; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; MLS000069475; 363960_ALDRICH; BPBio1_000382; Coscopin; Methoxyhydrastine; Prestwick0_000563; Prestwick2_000563; Noscapine (JP15/USP/INN); AC1NSW29; 5-[(1S)-4,5-dimethoxy-3-methylidene-1H-2-benzofuran-1-yl]-4-methoxy-6,9-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline; narcotine; Noscapine; gnoscopine; Noskapin; α-narcotine | C22H23NO7 | 413.42 g/mol | CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3 |
| TCMBANKIN061354 | Fumarine | C05189; TNP00339; 7-methyl-2,3:9,10-bis[methylenebis(oxy)]-7,13a-secoberbin-13a-one; ST036759; Bis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; Bis(1,3)benzodioxolo(4,5-c:5',6'-g)azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; HSCI1_000268; EINECS 204-999-6; AIDS-040935; Corydinine; 4,6,7,14-Tetrahydro-5-methyl-bis(1,3)benzodioxolo(4,5-c-5',6'-g)azecin-13(5H)-one; Oprea1_722246; NCGC00142402-01; Biflorine; Macleyine; 130-86-9; NCGC00017389-01; 7-methyl-6,8,9,16-tetrahydrobis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-15(7H)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:9,10-bis(methylenedioxy)-; Alk-3; 6164-47-2 (HCL); Oprea1_718853; AIDS040935; 7-Methyl-2,3:9,10-bis(methylenedioxy)-7,13a-secoberbin-13a-one; HSDB 3527; CHEBI:16415; AI3-62909; ACon1_001550; DTXSID00178935; Bis(1,3)benzodioxolo(5,6-c:5',6'-g)azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; Bis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6H)-one,5,7,8,15-tetrahydro-6-methyl-; AC1L4H3I; CHEMBL486179; 14-METHYL-7,9,20,22-TETRAOXA-14-AZAPENTACYCLO[15.7.0.0?,(1)(2).0?,(1)?.0(1)?,(2)(3)]TETRACOSA-1(24),4,6(10),11,17,19(23)-HEXAEN-2-ONE; CTK4F3162; MCULE-2865552640; BDBM50377937; 24240-05-9; AC1Q6P91; NCGC00385257-01_C20H19NO5_1,3-Benzodioxolo[5,6-c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; C20H19NO5; protopine ; Pseudoprotopine; MolPort-028-610-216; 6-methyl-5,7,8,15-tetrahydrobis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6h)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:10,11-bis(methylenedioxy)-; ZINC31502517; protopine | C20H19NO5 | 353.37 | CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3 |
| TCMBANKIN061462 | m-hemipicacid | metahemipic acid | C10H10O6 | 226.18 g/mol | COC1=C(C=C(C(=C1)C(=O)O)C(=O)O)OC |
| TCMBANKIN020949 | papaverine | Cepaverin; AOB5339; 58-74-2; MFCD00012745; ZINC00056555; NCI60_003183; Drapavel; DSSTox_RID_77939; NCI-C56359; Myobid; BB_NC-0726; H754; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride; Papaverine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Dynovas; Artegodan; Papavarine chlorhydrate; DTXSID9025825; NCGC00094258-03; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; Alapav; Papacon; AIDS000185; NSC35443 (HCL); SMR000058283; KBioGR_000914; Spasmo-Nit; Papavarine hydrochloride; HMS1569F08; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-isoquinoline; DSSTox_CID_5825; Papaverine hydrochloride (JP17/USP); Pameion; NCGC00094258-06; BSPBio_002153; Chlorhydrate de papaverine [French]; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride (1:1); SBB080541; AIDS-000185; Oprea1_387689; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; I01-13837; Optenyl; CTK8G2272; Papaverine Hcl; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Dispamil; Lopac0_000957; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Isoquinoline,7-dimethoxy-1-veratryl-, hydrochloride; MLS000028497; KBio2_005607; Lapav; Ro-Papav; Papanerin-HCl [German]; Cardiospan; Tox21_110226_1; TNP00305; Pavnell; HMS1920F06; LP00957; Pavagrant; SR-01000003098-2; SDCCGMLS-0003037.P003; AC1L1LRO; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 6,7-Dimethoxy-1-veratrylisoquinoline; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); TR-031684; Pavacot; Papaverine hydrochloride, United States Pharmacopeia (USP) Reference Standard; Paveron; Spectrum4_000467; Spectrum_000071; LS-267; SR-01000003098-11; Forpavin; Durapav; Cardoverina; Prestwick2_000583; Papaverine hydrochloride, powder; CCRIS 3804; 5-21-06-00182 (Beilstein Handbook Reference); Paverolan; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline; FT-0631269; ACon1_002094; NCGC00094258-04; EINECS 200-397-2; Papaverine; AC1Q3DLI; CHEMBL98123; Pavadel; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride; 58-74-2 (Parent); InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; REGID_for_CID_6084; BBC/116; Dipav; NCGC00094258-01; P0016; SPBio_002645; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; NCGC00261642-01; PubChem6305; Cerebid; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Oprea1_810508; Vasal; Papanerin; P 3510; 23473EC6BQ; Pharmakon1600-01500459; C06533; Lopac-P-3510; Vaso-Pav; SCHEMBL121268; DivK1c_000321; Papaverina [Italian]; NSC136630; NSC 136630; KBio2_000471; Spectrum3_000537; MLS002222208; component of Copavin; 58-74-2 (FREE BASE ); Therapav; BG00717685; Prestwick1_000583; Pavacen; Copavin; AK-67336; Dilaves; PAP H; 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene, chloride; UNII-23473EC6BQ; NCGC00015810-01; Papaversan; Tox21_500957; DSSTox_GSID_25825; Papaverine chlorohydrate; Papaverine hydrochloride [USAN:JAN]; EINECS 200-502-1; EU-0100957; Robaxapap; NCGC00094258-02; Papaverine hydrochloride [USP:JAN]; Papaverine, hydrochloride; Papaverine (hydrochloride); PAPAVERINE HYDROCHLORIDE; Prestwick0_000583; MEGxp0_001880; Delapav; D02218; Pavacap; BPBio1_000470; Ceraspan; AS-13262; NCGC00015810-03; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride; Papanerin-hcl; NCGC00015810-12; KB-146860; RS 47; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride; CAS-61-25-6; UOTMYNBWXDUBNX-UHFFFAOYSA-N; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1); Papaverin; ACon1_000238; KBio2_003039; Prestwick3_000583; Pavabid (TN); Papaverine monohydrochloride; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1 &GH; NSC757256; Pavatest; Papaverinium chloride; SR-01000003098; ST077145; ST023301; Pavakey; NSC-35443; BRN 0312930; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); SR-01000003098-9; 61-25-6 (HCL); SPBio_001015; NSC35443; MLS001148655; BSPBio_000426; IDI1_000321; Spectrum2_000978; Pavased; SPECTRUM1500459; Papanerine; NSC-757256; NCGC00094258-05; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)-isoquinoline hydrochloride; KBioSS_000471; HY-18077A; Papaverine hydrochloride, European Pharmacopoeia (EP) Reference Standard; BG01663857; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinolinehydrochloride; S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NINDS_000321; Papalease; Papaverine hydrochlorid; KBio3_001653; Pap-Kaps-150; MolPort-000-847-203; NCGC00015810-02; Isoquinoline, 6,7-dimethoxy-1-veratryl-; API0003748; CCG-40065; CS-5015; BAS 00674058; ARONIS23834; AKOS005111070; 61-25-6; NSC 35443; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; C20H22ClNO4; 1-(3,7-dimethoxyisoquinoline hydrochloride; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride (8CI); Tox21_110226; 6,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Spectrum5_001188; Opera_ID_1617; Prestwick_376; SR-01000003098-4; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; KBio1_000321 | C20H21NO4 | 339.39 | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC |
| TCMBANKIN028288 | morphine | (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 | C17H19NO3 | 285.34 | CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab